14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
NVCT vs ATYR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Nuvectis Pharma, Inc. (NVCT) in the Tradestie Institutional Equity Comparison Engine, winning 1–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). NVCT carries a Unified Composite Score of 53.4/100 (HOLD) at $19.07 (N/M Forward P/E, 0.0% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.83 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While NVCT currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (1–4 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: NVCT is currently in a Breakdown options structure phase (RSI 46.0); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVCT vs ATYR. Trailing 12-month operating profitability (NVCT 0.0% vs ATYR 0.0%) and valuation multiples (NVCT N/M vs ATYR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ NVCT vs ATYR Key Questions & Quantitative Answers
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Nuvectis Pharma, Inc. (NVCT) in the Tradestie Institutional Equity Comparison Engine, winning 1–4 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). NVCT carries a Unified Composite Score of 53.4/100 (HOLD) at $19.07 (N/M Forward P/E, 0.0% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.83 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While NVCT currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (1–4 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: NVCT is currently in a Breakdown options structure phase (RSI 46.0); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NVCT leads the Growth & Scale pillar: NVCT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NVCT generates N/A in USD-normalized revenue versus N/A for ATYR. In operating R&D and SG&A reinvestment, NVCT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.
NVCT and ATYR trade at balanced relative valuation multiples. NVCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVCT (-67.0% ROE) versus ATYR (-93.7% ROE) capital efficiency.
In options market volatility and institutional positioning, NVCT carries 72.4% implied volatility (9th %ile, Compressed (<25th %ile)), a 6.68x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.70β · 82% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.57β · 13806% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.